LETTER TO THE EDITOR
crossm than that of M. tuberculosis (4, 5) . Even for M. tuberculosis, it is questionable whether these MICs can be overcome by safe and tolerable doses of nifurtimox. Nifurtimox seems not to be a viable option for mycobacterial chemotherapy. Other nitrofuran derivates are still being investigated as new compounds against mycobacteria (10). We encourage these researchers to continue their work, as effective compounds against multidrug-and extensively drug-resistant TB and NTM disease remain direly needed.
